248 related articles for article (PubMed ID: 36811662)
1. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
[TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
3. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
7. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Wang Y; Lau W; Li Y; Tian Y; Lei Y; Wang J; Xia F
Int J Surg; 2023 Nov; 109(11):3590-3601. PubMed ID: 37598406
[TBL] [Abstract][Full Text] [Related]
8. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Pan GQ; Zhang X; Mao XC; Tan SY; Li RZ; Wang DX; Dong ZR; Yan YC; Li T
Expert Rev Anticancer Ther; 2024 May; 24(5):303-312. PubMed ID: 38623811
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.
Giannini EG; Bucci L; Garuti F; Brunacci M; Lenzi B; Valente M; Caturelli E; Cabibbo G; Piscaglia F; Virdone R; Felder M; Ciccarese F; Foschi FG; Sacco R; Svegliati Baroni G; Farinati F; Rapaccini GL; Olivani A; Gasbarrini A; Di Marco M; Morisco F; Zoli M; Masotto A; Borzio F; Benvegnù L; Marra F; Colecchia A; Nardone G; Bernardi M; Trevisani F;
Hepatology; 2018 May; 67(5):1784-1796. PubMed ID: 29159910
[TBL] [Abstract][Full Text] [Related]
11. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
[TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan.
Wu JS; Hong TC; Wu HT; Lin YJ; Chang TT; Wang CT; Liu WC; Hsieh MT; Wu IC; Chen PJ; Chen CY; Lin SH; Chuang CH; Han MZ; Chen HP; Tsai HM; Kuo HY
J Gastrointest Oncol; 2023 Apr; 14(2):849-862. PubMed ID: 37201085
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.
Chen ZH; Zhang XP; Zhou TF; Wang K; Wang H; Chai ZT; Shi J; Guo WX; Cheng SQ
Eur J Surg Oncol; 2019 Nov; 45(11):2188-2196. PubMed ID: 31256949
[TBL] [Abstract][Full Text] [Related]
17. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
[TBL] [Abstract][Full Text] [Related]
19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
20. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
